| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Pathology, Harvard Medical School and Brigham and Women’s Hospital, and
Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA 02115
PD-1, an inhibitory receptor expressed on activated lymphocytes, regulates tolerance and autoimmunity. We tested the role of PD-1:PD-1 ligand (PD-L) interactions in cross-presentation and the generation and control of CD8+ responses against self-Ag. Ag-naive PD-1–/– OVA-specific OT-I CD8+ T cells exhibited exacerbated responses to cross-presented Ag in mice expressing soluble OVA under the control of the rat insulin promoter (RIP-ovahigh). Following adoptive transfer into RIP-ovahigh recipients, PD-1–/– OT-I T cells expanded in the pancreatic lymph node. In contrast to wild-type OT-I cells, PD-1–/– OT-I T cells secreted IFN-
and migrated into the pancreas, ultimately causing diabetes. Loss of PD-1 affected CD8+ cells intrinsically, and did not significantly alter the responses of wild-type OT-I T cells adoptively transferred into the same RIP-ovahigh recipient mouse. PD-1:PD-L interactions also limited CD8+ effector cells, and PD-L1 expression on parenchymal tissues protected against effector OT-I T cell attack. Finally, we found that the loss of PD-1 on effector OT-I cells lowers the threshold for Ag recognition in peripheral tissues. These findings indicate two checkpoints where PD-1 attenuates self-reactive T cell responses: presentation of self-Ag to naive self-reactive T cells by dendritic cells in the draining lymph node and reactivation of pathogenic self-reactive T cells in the target organ.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This work was supported by National Institutes of Health Grants AI40614 and AI39671; the National Multiple Sclerosis Society (to A.H.S.); NIH Grant AI056299 (to A.H.S. and G.J.F.); and a Cancer Research Institute fellowship (to M.E.K.).
2 Address correspondence and reprint requests to Dr. Arlene H. Sharpe, Immunology Research Division, Department of Pathology, Harvard Medical School and Brigham and Women’s Hospital, Boston, MA 02115. E-mail address: arlene_sharpe{at}hms harvard.edu
3 Abbreviations used in this paper: DC, dendritic cell; ES, embryonic stem; ILN, inguinal lymph node; PD-1, programmed cell death-1; PD-L, programmed cell death ligand; PLN, pancreatic lymph node; RIP, rat insulin promoter; WT, wild type.
This article has been cited by other articles:
|
|
 |
|
  E. D. Reynoso and S. J. Turley Unconventional antigen-presenting cells in the induction of peripheral CD8+ T cell tolerance J. Leukoc. Biol., October 1, 2009; 86(4): 795 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Chen, C. W. Sham, A. M. Chan, L. M. Francisco, Y. Wu, S. Mareninov, A. H. Sharpe, G. J. Freeman, X.-J. Yang, J. Braun, et al. Role of the Immune Modulator Programmed Cell Death-1 during Development and Apoptosis of Mouse Retinal Ganglion Cells Invest. Ophthalmol. Vis. Sci., October 1, 2009; 50(10): 4941 - 4948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zhang, T. F. Gajewski, and J. Kline PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model Blood, August 20, 2009; 114(8): 1545 - 1552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chikuma, S. Terawaki, T. Hayashi, R. Nabeshima, T. Yoshida, S. Shibayama, T. Okazaki, and T. Honjo PD-1-Mediated Suppression of IL-2 Production Induces CD8+ T Cell Anergy In Vivo J. Immunol., June 1, 2009; 182(11): 6682 - 6689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. A. Parish, S. Rao, G. K. Smyth, T. Juelich, G. S. Denyer, G. M. Davey, A. Strasser, and W. R. Heath The molecular signature of CD8+ T cells undergoing deletional tolerance Blood, May 7, 2009; 113(19): 4575 - 4585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. D. Reynoso, K. G. Elpek, L. Francisco, R. Bronson, A. Bellemare-Pelletier, A. H. Sharpe, G. J. Freeman, and S. J. Turley Intestinal Tolerance Is Converted to Autoimmune Enteritis upon PD-1 Ligand Blockade J. Immunol., February 15, 2009; 182(4): 2102 - 2112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Gao, X.-Y. Wang, S.-J. Qiu, I. Yamato, M. Sho, Y. Nakajima, J. Zhou, B.-Z. Li, Y.-H. Shi, Y.-S. Xiao, et al. Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma Clin. Cancer Res., February 1, 2009; 15(3): 971 - 979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kovar, J. Tomala, H. Chmelova, L. Kovar, T. Mrkvan, R. Joskova, Z. Zakostelska, T. Etrych, J. Strohalm, K. Ulbrich, et al. Overcoming Immunoescape Mechanisms of BCL1 Leukemia and Induction of CD8+ T-Cell-Mediated BCL1-Specific Resistance in Mice Cured by Targeted Polymer-Bound Doxorubicin Cancer Res., December 1, 2008; 68(23): 9875 - 9883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. O. Alpdogan, S. X. Lu, N. Patel, S. McGoldrick, D. Suh, T. Budak-Alpdogan, O. M. Smith, J. Grubin, C. King, G. L. Goldberg, et al. Rapidly proliferating CD44hi peripheral T cells undergo apoptosis and delay posttransplantation T-cell reconstitution after allogeneic bone marrow transplantation Blood, December 1, 2008; 112(12): 4755 - 4764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Taglauer, A. S. Trikhacheva, J. G. Slusser, and M. G. Petroff Expression and Function of PDCD1 at the Human Maternal-Fetal Interface Biol Reprod, September 1, 2008; 79(3): 562 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Calbo, H. Delagreverie, C. Arnoult, F.-J. Authier, F. Tron, and O. Boyer Functional Tolerance of CD8+ T Cells Induced by Muscle-Specific Antigen Expression J. Immunol., July 1, 2008; 181(1): 408 - 417. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
